Pulse Biosciences launches first-in-human pulsed field ablation trial

US-based Pulse Biosciences has treated the first two patients with atrial fibrillation (AF) in the first-in-human feasibility study using its novel cardiac surgery system.

The two patients were treated at St Antonius Hospital in the Netherlands, initiating the first-in-human feasibility study. The patients tolerated the procedure well, said Pulse’s chief medical officer of cardiac surgery Gan Dunnington.